Stock Events

Stock Events

Spero Therapeutics 

€2.04
0
-€0.08-3.95% Tuesday 19:55

Statistics

Day High
2.16
Day Low
2.04
52W High
2.57
52W Low
0.51
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Oct 15
€0.01
Jul 15
€0.01
Apr 15
€0.01
Jan 15
€0.01
Oct 14
€0.01
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

19MayExpected
Q4 2025
Next
-0.17
0.04
0.25
0.46
Expected EPS
-0.1536102
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2HA.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap277.02B
Merck & Co. develops antibiotics and vaccines, directly competing with Spero's focus on bacterial infections.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a broad portfolio including anti-infectives, competing in the antibiotics market.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline has a significant presence in the antibiotics and vaccines market, overlapping with Spero's interests.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie has a growing portfolio in infectious diseases, including bacterial infections, competing with Spero's pipeline.
AMGEN
AMGN
Mkt Cap178B
Amgen's focus on biologics includes treatments that could compete with Spero's antibiotic therapies.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops treatments for infectious diseases, competing with Spero.
Novartis
NVS
Mkt Cap279.67B
Novartis has a diversified healthcare portfolio that includes antibiotics, directly competing with Spero Therapeutics.
Sanofi
SNY
Mkt Cap110.4B
Sanofi focuses on developing treatments for infectious diseases, including antibiotics, making it a competitor.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca has a strong presence in the infection, cardiovascular, and respiratory markets, competing with Spero's focus areas.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.7B
Teva Pharmaceutical Industries has a broad generic and specialty medicine portfolio, including antibiotics, competing in the same market as Spero.

About

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Ms. Esther P. Rajavelu
Employees
25
Country
United States
ISIN
US84833T1034

Listings

STU
DE
2HA.STU
MU
DE
2HA.MU
F
DE
2HA.F
XNAS
US
SPRO

0 Comments

Share your thoughts

FAQ

What is Spero Therapeutics stock price today?▼
The current price of 2HA.STU is €2.04 EUR — it has decreased by -3.95% in the past 24 hours. Watch Spero Therapeutics stock price performance more closely on the chart.
What is Spero Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Spero Therapeutics stocks are traded under the ticker 2HA.STU.
Is Spero Therapeutics stock price growing?▼
2HA.STU stock has fallen by -4.85% compared to the previous week, the month change is a -2.3% fall, over the last year Spero Therapeutics has showed a +296.5% increase.
When is the next Spero Therapeutics earnings date?▼
Spero Therapeutics is going to release the next earnings report on May 19, 2026.
What were Spero Therapeutics earnings last quarter?▼
2HA.STU earnings for the last quarter are 0.46 EUR per share, whereas the estimation was -0.17 EUR resulting in a +365% surprise. The estimated earnings for the next quarter are N/A EUR per share.
Does Spero Therapeutics pay dividends?▼
Yes, 2HA.STU dividends are paid quarterly. The last dividend per share was 0.01 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Spero Therapeutics have?▼
As of May 06, 2026, the company has 25 employees.
In which sector is Spero Therapeutics located?▼
Spero Therapeutics operates in the Other sector.
When did Spero Therapeutics complete a stock split?▼
Spero Therapeutics has not had any recent stock splits.
Where is Spero Therapeutics headquartered?▼
Spero Therapeutics is headquartered in Cambridge, United States.